Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
161 Anti-myeloid poly-pharmacy combined with FGFR4-targeted chimeric antigen receptors (CARs) effectively treats orthotopic rhabdomyosarcoma, modeling CAR effectiveness for solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.